1. - Clinica malattie apparato respiratorio

2. GESTIONE DELLA BPCO
CONCLUSIONI
La BPCO è sicuramente una malattia molto più
diffusa di quanto possa essere stimato sulla base delle
statistiche correnti. È una malattia per la quale si
dispone di strumenti idonei a fornire una diagnosi
in fase precoce, prima della comparsa di sintomi
rilevanti. Vi sono molti presupposti che rendono
plausibile un intervento di ricerca attiva di casi a
livello di medicina generale. Restano ancora non
dimostrate l’efficacia e l’efficienza di un simile intervento,
che sia posto a integrazione rispetto a misure
di prevenzione primaria sui principali fattori
di rischio.
BIBLIOGRAFIA
1. Petty TL: Scope of the COPD problem in North
America: early studies of prevalence and NHANES
III data: basis for early identification and intervention.
Chest 2000; 117 (5 Suppl. 2):326S-331S.
2. Viegi G, Scognamiglio A, Baldacci S et al: Epidemiology
of chronic obstructive pulmonary disease
(COPD). Respiration 2001; 68(1):4-19.
3. Mannino DM: COPD: epidemiology, prevalence,
morbidity and mortality, and disease heterogeneity.
Chest 2002; 121 (5 Suppl):121S-126S.
4. Mannino DM, Homa DM, Akinbami LJ et al: Chronic
obstructive pulmonary disease surveillance—
United States, 1971-2000. Respir Care 2002;
47(10):1184-1199.
5. Morrison AS: Screening in chronic disease. Oxford
University Press, New York Oxford, 1985.
6. Pistelli R, Sammarro S, Giuntini C: Storia naturale
e prognosi della BPCO. In Giuntini C, Fabbri LM,
Grassi V (Eds): I quaderni della BPCO – Il volto
della BPCO che cambia. UTET Periodici Scientifici,
Milano, 2002; 4:115-124.
7. Fletcher CM, Peto R,Tinker CM et al:The natural
history of chronic bronchitis and emphysema.
Oxford University Press, Oxford, 1976.
8. Global Initiative for Chronic Obstructive Lung Disease
(GOLD): NIH Publication No. 2701, Bethesda
MD, 2001.
9. Tattersall SF, Benson MK, Hunter D et al:The use
of tests of peripheral lung function for predicting
future disability from airflow obstruction in middle-aged
smokers.Am Rev Respir Dis 1978; 118(6):
1035-1050.
10. Vestbo J,Knudsen KM,Rasmussen FV:Predictive value
of the single-breath nitrogen test for hospitalization
due to respiratory disease. Lung 1990; 168(2):
93-101.
11. Viegi G, Pedreschi M, Pistelli F et al: Prevalence of
airways obstsruction in a general population. ERS
vs ATS definition. Chest 2000; 117:339S-345S.
12. Burrows B,Knudson RJ,Camilli AE et al:The “horse-racing
effect” and predicting decline in forced
expiratory volume in one second from screening
spirometry. Am Rev Respir Dis 1987; 135(4):788-
793.
13. Hardie JA,Buist AS,Vollmer WM et al:Risk of overdiagnosis
of COPD in asymptomatic elderly neversmokers.
Eur Respir J 2002; 20:1117-1122.
14. Enright PL e Crapo RO: Controversies in the use
of spirometry for early recognition and diagnosis of
chronic obstructive pulmonary disease in cigarette
smokers. Clin Chest Med 2000; 21(4):645-652.
15. McIvor RA e Tashkin DP: Underdiagnosis of chronic
obstructive pulmonary disease: a rationale for
spirometry as a screening tool. Can Respir J 2001;
8(3):153-158.
16. Ferguson GT, Enright PL, Buist AS et al: Office spirometry
for lung health assessment in adults: a consensus
statement from the National Lung Health
Education Program. Respir Care 2000; 45(5):513-
530.
17. Zielinski J e Bednarek M: Early detection of COPD
in a high-risk population using spirometric screening.
Chest 2001; 119(3):731-736.
18. Vestbo J e Lange P: Can GOLD Stage 0 provide
information of prognostic value in chronic obstructive
pulmonary disease Am J Respir Crit Care
Med 2002; 166(3):329-332.
19. van den Boom G, van Schayck CP, van Mollen MP
et al: Active detection of chronic obstructive pulmonary
disease and asthma in the general population.
Results and economic consequences of the
DIMCA program. Am J Respir Crit Care Med
1998; 158(6):1730-1738.
20. van Schayck CP, van Der Heijden FM, van Den
Boom G et al: Underdiagnosis of asthma: is the doctor
or the patient to blame The DIMCA project.
Thorax. 2000; 55(7):562-565.
21. van den Boom G, Rutten-van Molken MP, Molema
J et al:The cost effectiveness of early treatment
with fluticasone propionate 250 microg twice a day
in subjects with obstructive airway disease. Results
of the DIMCA program. Am J Respir Crit Care
Med 2001; 164(11):2057-2066.
51